Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has approved issue of duplicate share certificates requests in lieu of the original share certificates reported lost/misplaced.
Sanofi may underperform in near term; pricing control among key risks
The decline was largely on account of divestment of its nutraceutical business and a few key brands. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed:
Hold Sanofi India; target of Rs 6885: ICICI Direct
ICICI Direct recommended hold rating on Sanofi India with a target price of Rs 6885 in its research report dated July 27, 2022. Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed copies of the Notice to shareholders of the Company published today, in newspapers, Business Standard and Sakal.
Sanofi India Declares Special Dividend Of Rs 193 Per Equity Share
Earlier, the company announced that it has fixed August 8 as the record date for the purpose of payment of the one-time special interim dividend. Sanofi India Ltd - 500674 - Corporate Action-Board approves Dividend
Dear Sirs, The Board of Directors of the Company at its Meeting held today has declared One-Time Special Interim Dividend of Rs. 193 per equity share of Rs. 10 each for the financial year ending 31st December 2022. The Meeting of Board of Directors commenced at 2.00 p.m. and concluded at 5.10 p.m. As informed earlier the Company has fixed 8th August 2022 as the record date for the purpose of payment of the One-Time Special Interim Dividend. The said dividend will be paid on or after 22nd August 2022 Sanofi India Ltd - 500674 - Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended 30Th June 2022
We refer to our letter dated 6th July 2022 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 02.00 p.m. and concluded at 5.10 p.m. The Board approved unaudited financial results for the quarter and half year ended 30th June 2022. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of the unaudited financial results for the quarter and half year ended 30th June 2022 approved at this Meeting including the Statement of Assets and Liabilities as on that date and the Statement of Cash Flow for the half year ended 30th June 2022 along with a copy of the Limited Review Report duly signed by the Auditors of the Company.